CASP8 Polymorphisms Contribute to Cancer Susceptibility: Evidence from a Meta-analysis of 23 Publications with 55 Individual Studies

Overview

Journal Carcinogenesis

Specialty Oncology

Date 2010 Feb 24

PMID 20176653

Citations 21

Authors

Ming Yin

Jingrong Yan

Sheng Wei

Qingyi Wei

Affiliations

Soon will be listed here.

Abstract

Several potentially functional polymorphisms of CASP8 encoding an apoptotic enzyme, caspase 8, have been implicated in cancer risk, but individually published studies showed inconclusive results. We performed a meta-analysis of 23 publications with a total of 55 174 cancer cases and 59 336 controls from 55 individual studies. We summarized the data on the associations between three studied CASP8 polymorphisms (G>C D302H, -652 6N del and Ex14-271A>T) and cancer risk and performed subgroup analysis by ethnicity, cancer type, study design and etiology. We found that D302H CC and CG variant genotypes were associated with significantly reduced overall risk of cancers using conservative random genetic models [homozygote comparison: odds ratios (OR) = 0.79; 95% confidence interval (CI): 0.69-0.92; dominant comparison: OR = 0.93, 95% CI: 0.89-0.98; recessive comparison: OR = 0.81, 95% CI: 0.71-0.93). In further stratified analyses, the reduced cancer risk remained for subgroups of Caucasians, breast or estrogen-related cancers, and hospital- or population-based studies, except for an elevated risk for brain tumors. Similarly, the -652 6N del polymorphism was also associated with significantly reduced overall risk of cancers (homozygote comparison: OR = 0.84, 95% CI: 0.75-0.94; dominant comparison: OR = 0.88, 95% CI: 0.81-0.96; recessive comparison: OR = 0.90, 95% CI: 0.82-0.99) and all subgroups analyzed. However, the Ex14-271A>T polymorphism did not appear to have an effect on cancer risk. These results suggest that CASP8 D302H and -652 6N del polymorphisms are potential biomarkers for cancer risk.

Citing Articles

Caspase-8 in inflammatory diseases: a potential therapeutic target.

Zhang W, Zhu C, Liao Y, Zhou M, Xu W, Zou Z Cell Mol Biol Lett. 2024; 29(1):130.

PMID: 39379817 PMC: 11463096. DOI: 10.1186/s11658-024-00646-x.

Genetic contribution of caspase-8 variants and haplotypes to breast cancer risk and prognosis: a case-control study in Iran.

Afzaljavan F, Vahednia E, Barati Bagherabad M, Vakili F, Moezzi A, Hosseini A BMC Med Genomics. 2023; 16(1):72.

PMID: 37016353 PMC: 10071634. DOI: 10.1186/s12920-023-01484-0.

Transcriptome Signature of Immune Cells Post Reovirus Treatment in Mutated Colorectal Cancer.

Fogel E, Samouha A, Goel S, Maitra R Cancer Manag Res. 2021; 13:6743-6754.

PMID: 34475783 PMC: 8407676. DOI: 10.2147/CMAR.S324203.

Identification of FUBP1 as a Long Tail Cancer Driver and Widespread Regulator of Tumor Suppressor and Oncogene Alternative Splicing.

Elman J, Ni T, Mengwasser K, Jin D, Wronski A, Elledge S Cell Rep. 2019; 28(13):3435-3449.e5.

PMID: 31553912 PMC: 7297508. DOI: 10.1016/j.celrep.2019.08.060.

Association of caspase 8 polymorphisms -652 6N InsDel and Asp302His with progression-free survival and tumor infiltrating lymphocytes in early breast cancer.

Kuhlmann J, Bachmann H, Link T, Wimberger P, Krober E, Thomssen C Sci Rep. 2019; 9(1):12594.

PMID: 31467295 PMC: 6715668. DOI: 10.1038/s41598-019-47601-x.

References

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

Cybulski C, Wokolorczyk D, Gliniewicz B, Sikorski A, Gorski B, Jakubowska A . A six-nucleotide deletion in the CASP8 promoter is not associated with a susceptibility to breast and prostate cancers in the Polish population. Breast Cancer Res Treat. 2007; 112(2):367-8. DOI: 10.1007/s10549-007-9864-5. View

Hirschhorn J, Lohmueller K, Byrne E, Hirschhorn K . A comprehensive review of genetic association studies. Genet Med. 2002; 4(2):45-61. DOI: 10.1097/00125817-200203000-00002. View

Persson I . Estrogens in the causation of breast, endometrial and ovarian cancers - evidence and hypotheses from epidemiological findings. J Steroid Biochem Mol Biol. 2001; 74(5):357-64. DOI: 10.1016/s0960-0760(00)00113-8. View

Son J, Kang H, Chae M, Choi J, Park J, Lee W . Polymorphisms in the caspase-8 gene and the risk of lung cancer. Cancer Genet Cytogenet. 2006; 169(2):121-7. DOI: 10.1016/j.cancergencyto.2006.04.001. View

Lan Q, Morton L, Armstrong B, Hartge P, Menashe I, Zheng T . Genetic variation in caspase genes and risk of non-Hodgkin lymphoma: a pooled analysis of 3 population-based case-control studies. Blood. 2009; 114(2):264-7. PMC: 2714202. DOI: 10.1182/blood-2009-01-198697. View

Yang M, Sun T, Wang L, Yu D, Zhang X, Miao X . Functional variants in cell death pathway genes and risk of pancreatic cancer. Clin Cancer Res. 2008; 14(10):3230-6. DOI: 10.1158/1078-0432.CCR-08-0177. View

Enjuanes A, Benavente Y, Bosch F, Martin-Guerrero I, Colomer D, Perez-Alvarez S . Genetic variants in apoptosis and immunoregulation-related genes are associated with risk of chronic lymphocytic leukemia. Cancer Res. 2008; 68(24):10178-86. DOI: 10.1158/0008-5472.CAN-08-2221. View

Shephard N, Abo R, Rigas S, Frank B, Lin W, Brock I . A breast cancer risk haplotype in the caspase-8 gene. Cancer Res. 2009; 69(7):2724-8. PMC: 2730164. DOI: 10.1158/0008-5472.CAN-08-4266. View

10.

Wei Q, Cheng L, Amos C, Wang L, Guo Z, Hong W . Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst. 2000; 92(21):1764-72. DOI: 10.1093/jnci/92.21.1764. View

11.

Sun T, Gao Y, Tan W, Ma S, Shi Y, Yao J . A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat Genet. 2007; 39(5):605-13. DOI: 10.1038/ng2030. View

12.

Qiu D, Kurosawa M, Lin Y, Inaba Y, Matsuba T, Kikuchi S . Overview of the epidemiology of pancreatic cancer focusing on the JACC Study. J Epidemiol. 2005; 15 Suppl 2:S157-67. PMC: 8639044. DOI: 10.2188/jea.15.s157. View

13.

Ramus S, Vierkant R, Johnatty S, Pike M, Van Den Berg D, Wu A . Consortium analysis of 7 candidate SNPs for ovarian cancer. Int J Cancer. 2008; 123(2):380-388. PMC: 2667795. DOI: 10.1002/ijc.23448. View

14.

Sasco A, Secretan M, Straif K . Tobacco smoking and cancer: a brief review of recent epidemiological evidence. Lung Cancer. 2004; 45 Suppl 2:S3-9. DOI: 10.1016/j.lungcan.2004.07.998. View

15.

Lobanova Y, Scherbakov A, Shatskaya V, Krasilnikov M . Mechanism of estrogen-induced apoptosis in breast cancer cells: role of the NF-kappaB signaling pathway. Biochemistry (Mosc). 2007; 72(3):320-7. DOI: 10.1134/s0006297907030108. View

16.

Bethke L, Sullivan K, Webb E, Murray A, Schoemaker M, Auvinen A . CASP8 D302H and meningioma risk: an analysis of five case-control series. Cancer Lett. 2008; 273(2):312-5. DOI: 10.1016/j.canlet.2008.08.010. View

17.

Ulybina Y, Kuligina E, Mitiushkina N, Rozanov M, Ivantsov A, Ponomariova D . Coding polymorphisms in Casp5, Casp8 and DR4 genes may play a role in predisposition to lung cancer. Cancer Lett. 2009; 278(2):183-191. DOI: 10.1016/j.canlet.2009.01.012. View

18.

Gilot D, Serandour A, Ilyin G, Lagadic-Gossmann D, Loyer P, Corlu A . A role for caspase-8 and c-FLIPL in proliferation and cell-cycle progression of primary hepatocytes. Carcinogenesis. 2005; 26(12):2086-94. DOI: 10.1093/carcin/bgi187. View

19.

Wang M, Zhang Z, Tian Y, Shao J, Zhang Z . A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter associated with risk and progression of bladder cancer. Clin Cancer Res. 2009; 15(7):2567-72. DOI: 10.1158/1078-0432.CCR-08-2829. View

20.

Au W, Abdou-Salama S, Sierra-Torres C, Al-Hendy A . Environmental risk factors for prevention and molecular intervention of cervical cancer. Int J Hyg Environ Health. 2006; 210(6):671-678. DOI: 10.1016/j.ijheh.2006.10.003. View